Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Recurrence 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Rituximab 3Brentuximab Vedotin 2venetoclax 1veltuzumab 1pirtobrutinib 1ontuxizumab 1iratumumab 1exatecan 1durvalumab 1Zidovudine 1Vincristine 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Prednisone 1Prednisolone 1Oxaliplatin 1Mitoxantrone 1Mannose-Binding Lectin 1Lenalidomide 1Gemcitabine 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bendamustine Hydrochloride 1Antibodies, Monoclonal 1Adrenal Cortex Hormones 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Dendritic Cell Sarcoma, Interdigitating × iratumumab × Clear all
NCT00298467 2010-04-26

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Bristol-Myers Squibb

Phase 2 Withdrawn
45 enrolled
DermatologicLymphoidSarcoma

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡